Executive Summary / Key Takeaways
-
The Smokeless Transformation Is Working: BAT added 4.7 million smokeless consumers in 2025 to reach 34.1 million total, with Modern Oral revenue surging 48% and New Categories contribution margin expanding 280 basis points to 10.6%. This demonstrates the company can build new growth engines with improving economics, not just fund them indefinitely.
-
U.S. Market Inflection Validates Strategy: U.S. combustibles returned to revenue growth (+4.6% constant currency) for the first time since 2022, while Modern Oral revenue exploded 310% to £317 million, making Velo Plus the #2 brand nationally within a year. BAT appears to have cracked the code on competing in America's largest nicotine profit pool, creating a dual engine of combustible cash generation and smokeless growth.
-
Financial Discipline Underpins Transition: Despite investing heavily in transformation, BAT maintains 95% cash conversion, is deleveraging toward its 2-2.5x EBITDA target, and returns capital through a 5.7% dividend yield and £1.3 billion buyback. The smokeless pivot is financially sustainable without diluting shareholders—a critical differentiator from peers burning cash on NGPs.
-
Valuation Discount Reflects Market Skepticism: Trading at 12.3x earnings and 10.7x EV/EBITDA versus Philip Morris International (PM) at 22.5x and 16.0x, the market prices BTI as a declining tobacco company, not a transforming consumer products business. This creates potential upside if BAT delivers on its 2026 guidance of 3-5% revenue growth and 4-6% profit growth.
-
Illicit Trade Is the Critical Variable: With 70% of the U.S. vapour market and 65% of Australia's combustible market estimated to be illicit, enforcement levels will determine whether legal products can capture share and pricing power. This is the single biggest swing factor for both near-term results and long-term category viability.
Setting the Scene: A 123-Year-Old Company Reinventing Itself
British American Tobacco, headquartered in London and tracing its origins to a 1902 joint venture between Imperial Tobacco (IMB) and American Tobacco, has spent the past decade executing one of the most ambitious transformations in consumer goods history. The company that built its empire on cigarettes is now explicitly committed to becoming a "predominantly smokeless business by 2035," targeting over 50% of revenue from reduced-risk products. This is a complete redefinition of what BAT is and how it makes money.
The industry structure makes this transformation both necessary and possible. The global legal tobacco and nicotine market was valued at $939 billion in 2024, but the core combustible segment is in structural decline, with legal cigarette volumes forecast to fall 0.2% annually through 2029. Meanwhile, reduced-risk products are growing rapidly: Heated Products volume is expected to expand 28% from 2024-2029, nicotine pouches by 130%, while vapour remains flat. Critically, the number of global adult smokers is projected to decrease by 20 million by 2028, but total nicotine users are migrating to alternative formats. BAT's strategy is to follow this migration, capturing value in the $1.2 trillion combined nicotine and cannabis markets expected by 2029.
BAT sits as the clear #2 global player behind Philip Morris International, with an estimated 15% share of the total tobacco/NGP market based on revenue. Unlike Altria Group (MO) U.S.-centric model or Imperial Brands' regional focus, BAT's true differentiator is its balanced global footprint and multi-category approach. While Philip Morris leads in heated tobacco with 76% global share through IQOS, BAT is building strength across vapour (Vuse), modern oral (Velo), and heated products (glo). This diversification reduces dependence on any single technology or regulatory regime, creating multiple paths to the 2035 smokeless revenue target.
Technology, Products, and Strategic Differentiation: Winning in Modern Oral
BAT's transformation success hinges on product innovation that delivers tangible consumer benefits while building defensible moats. The standout performer is Modern Oral, where Velo has achieved global volume share leadership by end of 2025, capturing 33.4% category share in top markets—up 7.5 percentage points year-over-year. Modern Oral represents the fastest-growing, highest-margin opportunity in nicotine alternatives, and BAT has established clear leadership.
Velo Plus, launched nationally in the U.S. in late 2024, reached the #2 position in both volume and value share within its first year, gaining nearly 18 percentage points of volume share. The product addresses a critical gap: while Zyn (Philip Morris) dominated the premium segment, Velo Plus offered a differentiated experience that resonated with poly-users switching from traditional oral tobacco. The FDA's new pilot program to streamline PMTA reviews for nicotine pouches further validates the category's role in harm reduction, potentially accelerating legal market growth. For investors, this regulatory support reduces the risk of sudden category bans and legitimizes BAT's investments.
In vapour, Vuse maintains global value share leadership in rechargeable closed systems and disposables despite a 8.6% revenue decline in 2025. The headwind is clear: illicit single-use products represent 70% of the U.S. vapour market, flooding channels with unregulated, untaxed products. This explains why Vuse's volume declined 8.8% in the U.S. while still gaining 2 percentage points of value share to 51.7%—BAT is competing for value, not volume, focusing on premium products like Vuse Ultra that offer connected, personalized experiences. If federal and state enforcement meaningfully reduces illicit trade, Vuse is positioned to capture the majority of returning volume, as seen in Louisiana where enforcement drove volume back to legal channels.
Heated products present BAT's biggest technology challenge. Glo Hyper faces intense competitive pressure from IQOS in Japan and South Korea, with category volume share declining 1.5 percentage points. The new glo Hilo platform, launched in 2025 with dual-heating technology and tobacco-free consumables, is designed to establish a premium segment presence. While early results are encouraging, BAT lags Philip Morris's 76% global heated tobacco share. Heated products represent the largest NGP profit pool after vapour, and BAT's slower adoption rate means it's ceding ground in a category that could drive long-term margins. The upcoming glo Hyper next-generation device launching Q2 2026 is critical—failure to gain traction would relegate BAT to a follower position in the most profitable smokeless segment.
Financial Performance & Segment Dynamics: Combustibles Funding the Future
BAT's 2025 results provide evidence that the transformation strategy is working, with combustibles generating the cash to fund New Categories growth while those businesses rapidly improve their economics. Group revenue declined 1% reported to £25.6 billion but grew 2.1% constant currency, with the U.S. market driving performance through robust price/mix management.
The Combustibles segment generated £20.2 billion in revenue (78.9% of total) despite a 7.9% volume decline. Revenue still grew 1% constant currency through pricing power and excise duty drawbacks, particularly in the U.S. where revenue increased 4.6% despite a 7.7% volume drop. This pricing elasticity demonstrates BAT's brand strength and the inelastic demand for nicotine, providing a stable cash cow that funded £648 million in capital expenditure and £1.3 billion in share buybacks. As long as combustibles can maintain positive revenue growth, the transformation is self-funded, eliminating the dilution risk that plagues many corporate turnarounds.
New Categories revenue grew 7% constant currency to £3.6 billion, but the real story is the margin expansion. Category contribution jumped 77% to £442 million, with margins up 280 basis points to 10.6%. The business is scaling—fixed costs are being spread over a rapidly growing revenue base, and disciplined investment in high-value markets is paying off. Modern Oral drove this improvement with 48% revenue growth, while Heated Products grew only 1% and Vapour declined 8.6%. BAT's capital allocation is working: it's winning where it matters most (Modern Oral) and managing decline where competition is fiercest (Vapour illicit trade).
The U.S. performance is particularly instructive. Modern Oral revenue surged 310% to £317 million, with Velo Plus achieving positive category contribution within its first year. Meanwhile, U.S. combustibles delivered strong profit growth through enhanced revenue management and a 30 basis point gain in value share. This dual success proves BAT can simultaneously manage its legacy business for cash while building new growth engines.
Balance sheet strength underpins the entire strategy. Net debt of £31.2 billion is stable year-over-year, and the company maintains investment-grade ratings. With £5 billion in undrawn revolving credit facilities and debt maturities of £2.4 billion in 2026 and £2.9 billion in 2027, liquidity is ample. The £1.3 billion share buyback for 2026, up from £1.1 billion in 2025, signals management confidence while the 5.73% dividend yield provides downside protection. BAT is not sacrificing financial health for transformation, maintaining the capital return profile that tobacco investors expect while investing in future growth.
Outlook, Management Guidance, and Execution Risk
Management's 2026 guidance frames a pivotal year for BAT's transformation. The company targets 3-5% revenue growth, 4-6% adjusted profit growth, and 5-8% adjusted EPS growth—its "midterm algorithm"—but expects to be at the lower end of these ranges with second-half weighted profit performance. This phasing reflects deliberate investment timing: New Categories spending is front-loaded while Fit to Win savings build through the year, creating a J-curve effect.
The U.S. market assumptions are critical to this guidance. Management expects combustible industry volume declines to moderate to 6-7% long-term, with BAT achieving 0-1% revenue growth through pricing and mix optimization. For Vuse, they assume stable volumes in 2026 as enforcement against illicit products takes time to impact. This sets a conservative baseline—any meaningful federal or state action against illegal vapes would drive upside to both volume and pricing power.
Modern Oral is expected to drive low double-digit New Categories growth, with the U.S. category projected to almost double over the next two years. This suggests Velo's momentum is sustainable and the 310% growth in 2025 isn't a one-time spike. The global leadership position, with volumes 6x larger than the nearest competitor in AME , provides a foundation for international expansion that diversifies away from U.S. regulatory risk.
Key execution risks center on competitive response and regulatory timing. Philip Morris's IQOS holds 76% of the global heated tobacco market, and its Zyn brand remains the U.S. Modern Oral leader. If PM accelerates innovation or engages in price competition, BAT's share gains could stall. Similarly, if the FDA delays enforcement against illicit vapes or revisits menthol restrictions, Vuse's recovery could be delayed. These represent external variables beyond BAT's control that could impact the 2026 algorithm.
Risks and Asymmetries: What Could Break the Thesis
The illicit trade threat is the most material risk to BAT's transformation. With 70% of the U.S. vapour market and 65% of Australia's combustible market estimated to be illegal, the legal industry's growth potential is artificially constrained. Illicit products avoid excise taxes, enabling prices 30-50% below legal alternatives, which pressures BAT's ability to take price increases and erodes volume. If enforcement remains weak, the New Categories growth story could stall regardless of product quality. Meaningful enforcement, as seen in Louisiana's vapor directory, drives immediate volume recapture to legal leaders like Vuse.
Regulatory uncertainty creates a second major risk vector. While the Trump administration withdrew proposed menthol and nicotine limit rules, these could be reinstated under future leadership. A menthol ban would disproportionately impact Newport, BAT's premium U.S. brand, potentially reducing U.S. combustible profits by 15-20%. The FDA's pilot program for Modern Oral is positive, but disproportionate regulation of smokeless products could emerge, particularly around flavor restrictions. This creates a binary outcome: supportive regulation accelerates adoption, while restrictive regulation could make the 2035 smokeless target unattainable.
Heated product competitiveness remains a strategic vulnerability. Glo's 1% revenue growth and 1.5 percentage point share loss in top markets indicate BAT is losing ground to IQOS. If the glo Hilo and next-generation Hyper devices launching in 2026 fail to close the performance gap, BAT could be permanently relegated to a secondary position in the most profitable smokeless segment. Failure here would force BAT to rely more heavily on lower-margin oral and vapour categories, compressing long-term margin potential.
Geopolitical exposure and supply chain complexity create operational risks. The company's global footprint leaves it vulnerable to trade disruptions like Red Sea shipping attacks, while the New Categories supply chain's multi-tiered structure faces single-supplier dependencies. Climate change poses physical risks—BAT suffered £8 million in losses from a 2023 U.S. tornado and £11 million from 2024 UAE floods. These risks create earnings volatility and could disrupt product launches at critical moments.
Valuation Context: Discounted Transformation Story
At $57.80 per share, BAT trades at 12.3x trailing earnings and 10.7x EV/EBITDA, a significant discount to Philip Morris (22.5x P/E, 16.0x EV/EBITDA) and modest discount to Altria (16.1x P/E, 8.5x EV/EBITDA). The 5.73% dividend yield is well-covered by a 68.7% payout ratio and supported by 95% operating cash conversion. This valuation reflects market skepticism that BAT can successfully transform before combustibles decline overwhelms growth.
The free cash flow yield of approximately 6.1% ($7.68 billion FCF / $125.24 billion market cap) provides a floor for valuation, particularly given the company's commitment to returning cash. BAT's enterprise value of $166.65 billion represents 4.9x TTM revenue, in line with slower-growing consumer staples but well below typical NGP valuations. If BAT achieves its 2026 guidance and demonstrates sustained New Categories margin expansion, the multiple could re-rate toward Philip Morris levels, implying 50-80% upside potential.
Relative to peers, BAT's 0.07 beta indicates lower market sensitivity, while its 15.8% ROE lags Philip Morris's implied ROE but exceeds Imperial Brands' 38.7% (which reflects higher leverage rather than operational efficiency). The debt-to-equity ratio of 0.73 is conservative for the sector, providing flexibility for continued investment. BAT is taking a measured approach to transformation rather than over-leveraging to chase growth, reducing downside risk if the smokeless transition faces headwinds.
Conclusion: A Transformation at the Tipping Point
British American Tobacco stands at a critical inflection point where its smokeless transformation is transitioning from promise to proof. The 2025 results demonstrate that combustibles can still generate growth and cash while New Categories, led by Modern Oral's exceptional 48% revenue expansion, are rapidly scaling with improving economics. The U.S. market's return to revenue growth and Velo Plus's meteoric rise to #2 share position validate that BAT can compete and win in the world's most important nicotine profit pool.
The investment thesis hinges on two variables: illicit trade enforcement and competitive dynamics in heated products. If U.S. federal and state authorities meaningfully crack down on illegal vapour products, Vuse is positioned to recapture volume and accelerate profit growth. If glo's 2026 device launches can close the gap with IQOS, BAT will have a complete portfolio of competitive smokeless products. Failure on either front would relegate the company to a regional player in oral nicotine while ceding the largest categories to Philip Morris.
Trading at 12.3x earnings with a 5.7% dividend yield, BAT offers a compelling risk/reward profile for investors willing to look through near-term headwinds. The market's valuation discount reflects legitimate skepticism about tobacco's future, but it ignores the tangible progress toward a smokeless model with superior economics. With management committed to delivering 3-5% revenue growth by 2026 and the balance sheet supporting both transformation investment and capital returns, BAT has the financial firepower to prove the doubters wrong. The smokeless world is coming; BAT is building it while paying investors to wait.
